Markus B Heckmann

6PUBLICATIONS
24CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 04, 2026
HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity.

|Aug 18, 2026
MCL-1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model.

|Jun 16, 2025
Feasibility Study for Long-Term Cardiotoxicity in Dose-Dense Treated Cancer Patients.

Markus B Heckmann, Julia Lehmann, Daniel Finke

|Jun 15, 2023
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.

Lorenz H Lehmann, Markus B Heckmann, Guillaume Bailly

|Jun 02, 2021
Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation.

Daniel Finke, Markus B Heckmann, Janek Salatzki

|Apr 24, 2020
AAV-mediated cardiac gene transfer of wild-type desmin in mouse models for recessive desminopathies.

T Ruppert, M B Heckmann, K Rapti

Pageof 1

Frequent Collaborators

5 joint publications

Lorenz H Lehmann

3 joint publications

Daniel Finke

2 joint publications

Oliver J Müller

2 joint publications

Ziya Kaya